A phase I study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A
Jimeno, Antonio, Opyrchal, Mateusz, Diamond, Jennifer Robinson, Fountzilas, Christos, Corr, Bradley, Bezi, Ildiko, Wang, Hui, Kwan, Rudolf, Zhi, Jay, Cutler, David, Boland, Patrick McKay
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article